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Our aim is the identiﬁcation and correlation of changes in tumor-associated protein expression which results from therapy. LNCaP
tumors, excised from nude mice treated either by orchiectomy or with the chemotherapeutic agent paclitaxel, were evaluated for the
expression of proteins and receptors associated with growth, diﬀerentiation, and angiogenesis using immunohistologic procedures.
Compared to untreated control tumors, both treatments reduced the expression of vascular endothelial growth factor (VEGF),
prostate-speciﬁcmembraneantigen(PSMA),prostate-speciﬁcantigen(PSA),androgenreceptor(AR),andepidermalgrowthfactor
receptor (EGFR). The eﬀect of paclitaxel treatment on AR expression was the most signiﬁcant (P = .005). Of particular interest was
identifying a signiﬁcant correlation (P<. 000801) between PSMA and VEGF expression regardless of treatment modality. These
altered expressions suggest that PSMA may also be a marker for angiogenesis and could represent a target for deliverable agents
recognizingeitherprostatictumorsorendothelialdevelopment.CellsurfacePSMAwouldthenpresentauniquetargetfortreatment
of patients early in their development of prostatic metastases.
INTRODUCTION
Prostate-speciﬁc membrane antigen (PSMA) has
gained increased attention as a marker for prostate can-
cer. Unlike the well-characterized and secreted prostate-
speciﬁc antigen (PSA), PSMA remains cell associated
and can be internalized, acting as if it were a receptor
molecule. PSMA is also characterized as folate hydrolase
(FOLH-1) and this activity [1] makes it a good candidate
for prodrug activation [2]. In addition, its peptides have
been utilized in a vaccine associated with antigen pre-
senting dendritic cells [3]. Favorable responses have been
noted in several clinical trials of these vaccines [4, 5, 6, 7].
Although the prostate has the greatest PSMA expression,
it is also found in the brain, salivary glands, the small
intestine [8], as well as endothelial cells associated with
many solid tumors [8]. Therefore it has been suggested
that PSMA may be utilized both as a marker and as a
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therapeutic target [8]. In addition to its potential for pro-
drug activation, it has also been considered a target for
radiotherapy.Indeed,theJ591monoclonalantibody,with
speciﬁcityfortheextracellulardomainofPSMA,hasbeen
showntodeliveralpha-emittingradiationtoprostatecan-
cer cells both in vitro and in vivo using the LNCaP
model [9, 10]. Other monoclonals (7E11, J415, Hybritech
PEQ226.5, PM2J004.5, in addition to J591) would appear
to have similar potential with reactivity against renal car-
cinoma, transitional cell carcinoma of the urinary blad-
der, testicular embryonal carcinoma, colonic and neu-
roendocrine carcinomas, glioblastoma multiforme, ma-
lignant melanoma, as well as pancreatic duct, nonsmall
cell lung, soft tissue, and breast carcinomas [11]. In an ef-
fort to associate the expression of PSMA with additional
markers associated with growth, diﬀerentiation, or angio-
genesis, we utilized histologic sections prepared for a pre-
viousstudy[12] and evaluatedfurtherspeciﬁc protein ex-
pression following two therapeutic modalities.
In a previous study [12], utilizing LNCaP tumors car-
ried in athymic nude mice, we evaluated the eﬀect of
paclitaxel, thalidomide, and orchiectomy upon markers
associated with growth, diﬀerentiation, and angiogene-
sis. We reported signiﬁcant (P ≤ .001) eﬀects of pacli-
taxel therapy resulting in diminished tumor volume, Bcl-
2, cyclin D, and PSA expression, and serum PSA levels.
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in fewer markers. Bcl-2 expression was elevated (P ≤
.011), and tissue PSA expression dropped (P ≤ .002).
Orchiectomy also signiﬁcantly (P ≤ .001) raised Bcl-2
immunoreactivity and was accompanied with a signiﬁ-
cant (P ≤ .002) decrease in tumor volume.
In this additional study the following proteins asso-
ciated with growth, diﬀerentiation, or angiogenesis were
further evaluated using immunohistologic techniques.
Vascular endothelial growth factor (VEGF) is a pro-
tein released by many tumors which stimulates the di-
rected growth of endothelial cells toward malignancies,
resulting in increased vascularity through the process of
angiogenesis.
PSMA and PSA are both well-characterized markers
forprostatetissueandareexpressedinmostdiﬀerentiated
tumors. These markers may provide suitable targets for
the selective delivery of new therapeutic agents.
The androgen receptor (AR) is also a marker for
prostate tumor diﬀerentiation and is currently being eval-
uated for eﬃcacy in speciﬁc targeting.
The epidermal growth factor receptor (EGFR) is an
important binding site for several growth stimulatory lig-
ands, including transforming growth factor-alpha (TGF-
α) and EGF. EGFR is overexpressed in many tumors and
its kinase activity has become the preferential target for
new therapeutic agents which utilize either monoclonal
antibodies [13], antisense oligonucleotides [14], or vari-
ous small domain speciﬁc molecules.
Paclitaxel (taxol) is an antimicrotubule agent which
promotes the assembly of microtubules from tubulin
dimers and prevents their depolymerization. This stabi-
lization prevents the dynamic reorganization of the mi-
crotubule network necessary for vital interphase and mi-
totic cellular functions. Paclitaxel also induces abnor-
mal bundles of microtubules during the cell cycle and
promotes the formation of multiple microtubule asters
during mitosis [15]. These processes appear to account
for most of paclitaxel antitumor activity, resulting in a
blockade at the transition point between metaphase and
anaphase during mitosis. The cell is then directed towards
an apoptotic death pathway [16]p r e s u m a b l ya c c o m p a -
nied with a decrease in Bcl-2 expression, as observed in
our earlier study [12].
Orchiectomy is the “gold standard” for the treatment
of advanced prostate cancer; however, relapse occurs in
most patients following an average of 2.5 years, and the
progressing metastatic tumors are usually hormone in-
sensitive. New therapies are very much required for ad-
vancing prostate cancer and a greater understanding of
the angiogenic process could produce new targets for in-
hibition.
METHODS
LNCaPtumorline
The LNCaP human prostate cancer cell line was pur-
chased from the American Tissue Culture Collection
(ATCC) and maintained in RPMI 1640 in a 5%-CO2 at-
mosphere at 37◦C. 2.4–2.6 × 106 in vitro propagated cells
were suspended in 0.5mL of RPMI and mixed with an
equal volume of Matrigel. The 1-mL volume was im-
planted subcutaneously into the right ﬂank of nude mice.
Tumors took approximately 6 weeks to appear and had a
take rate of greater than 75%.
Animals
Athymic nude mice (nu/nu) were purchased from
Harlan Sprague-Dawley (Indianapolis, Ind) and main-
tained in a sterilized environment according to guide-
linesestablishedbytheUSDepartmentofAgricultureand
the American Association for Accreditation of Laboratory
Animal Care (AAALAC). This project was approved by
the Institutional Animal Care and Utilization Committee
(IACUC) of the Cook County Hospital and the Hektoen
Institute.
Paclitaxel
Paclitaxel (taxol) drug [15] is derived by a semisyn-
thetic process from Taxus baccata, has a molecular weight
of 853.9 and an empirical formula of C14H51NO14,a n d
was obtained from Bristol-Myers Squibb.
Treatmentgroups
Athymicnude mice wereinoculated with2.4–2.6×106
in vitro propagated LNCaP cells into the right-ﬂank posi-
tion. Fifteen nonnecrotic tumors which exceeded 1cm in
diameter were randomly divided into three groups of ﬁve
for treatment as follows:
(1) group 1: controls; no treatment,
(2) group2:treatedwithpaclitaxel(20mg/kg×5d a y s ) ,
(3) group 3: orchiectomy.
Therapyschedule
Therapy was begun when tumors exceeded 1cm in
diameter. The experiment was terminated by euthana-
sia 6 weeks later when the tumors were excised and
paraﬃn embedded for immunohistochemistry. As previ-
ously reported [12] treated tumors signiﬁcantly dimin-
ished in size with therapy, whereas the controls continued
to progress in volume.
Markerdeterminationandstatisticalevaluation
Immunohistochemistry was performed as previously
described [8] for VEGF (Santa Cruz; Santa Cruz, Calif),
PSMA (Cytogen Corporation, Princeton, NJ), PSA (Santa
Cruz), AR (Santa Cruz), EGFR (Santa Cruz), and graded
on a 0-to-5 (greatest) immunoreactive scale. This quali-
tative assessment of staining took into consideration both
the area stained and its intensity for the numerous ﬁelds
evaluated. Each individual specimen and its derived repli-
cateslides(atleasttwo)wereevaluatedby4–5individuals.
Evaluations were performed randomly, in the blind and2005:3 (2005) Correlation Between PSMA and VEGF Expression 289
Table 1. Immunohistochemical staining.
Group VEGF PSMA PSA AR EGFR
Control 2.40 ±2.01 2.67 ±1.98 2.00 ±2.35 3.87 ±1.44 ↑ 2.32 ±1.48
Orchiectomy 1.37 ±1.13 1.80 ±0.30 0.60 ±0.89 2.13 ±1.22 | 1.58 ±0.90
Paclitaxel 1.26 ±1.54 1.08 ±1.12 0.10 ±0.22 1.06 ±0.75 ↓ 1.68 ±1.28
P v a l u e ———.005 —
Table 2. Correlation∗ between marker expression.
Group Statistics PSMA PSA AR EGFR
VEGF
Correlation 0.769 0.306 0.0383 0.0836
P value 0.000801 0.267 0.892 0.767
N 15 15 15 15
PSMA
Correlation 0.418 0.197 0.0587
P value — 0.121 0.481 0.835
N 15 15 15
PSA
Correlation 0.797 0.113
P value — — 0.000375 0.689
N 15 15
AR
Correlation 0.296
P value — — — 0.284
N 15
∗Pearson product moment correlation.
on diﬀerent occasions, then means and standard devia-
tions were determined. Only nonnecrotic ﬁelds were eval-
uated. When possible, sequential sections prepared from
the same embedded block were stained for the various
markers. Statistical signiﬁcance was evaluated by Sigma
Stats Solutions 2.03 software (AB, Canada).
RESULTS
Table 1 lists the means and standard deviations which
resulted from multiple (blind) evaluations of slides by the
investigators. Control values (± SD) obtained by stain-
ing with speciﬁc antibodies were 2.40 ± 2.01 for VEGF,
2.67 ± 1.98 for PSMA, 2.00 ± 2.35 for PSA, 3.87 ± 1.44
for AR, and 2.32±1.48 for EGFR. Values obtained follow-
ing orchiectomy were 1.37 ± 1.13 for VEGF, 1.80 ± 0.30
for PSMA, 0.60 ± 0.89 for PSA, 2.13 ± 1.22 for AR, and
1.58 ± 0.90 for EGFR. Values obtained for the paclitaxel
group were 1.26 ± 1.54 for VEGF, 1.08 ± 1.12 for PSMA,
0.10 ± 0.22 for PSA, 1.06 ± 0.75 for AR, and 1.68 ± 1.28
for EGFR. Although all values were diminished following
both treatment modalities, signiﬁcance (P = .005) was
only found in AR expression between controls and those
tumors treated with paclitaxel.
Table 2 lists the correlation coeﬃcients obtained be-
tweenallgroupsandthevariousproteinmarkers.Acorre-
lation coeﬃcient of 0.769 was obtained by Pearson prod-
uct moment correlation between VEGF and PSMA. This
had a signiﬁcance of P = .000801. Variations in tumor
volume or in the amount of tissue necrosis did not appear
to inﬂuence expression of either protein.
DISCUSSION
Prostate cancer has the highest incidence of any hu-
man malignancy and is second only to lung cancer in
male mortality [17]. Although localized prostate cancer
can be cured by either radical prostatectomy or radiation
therapy, regional involvement usually proceeds to become
a metastatic disease. Obviously newer chemotherapeutic
compounds are needed and antiangiogenic therapy could
theoretically have potential eﬃcacy. In an eﬀort to eval-
uate newer agents we treated human LNCaP tumors car-
riedinnudemicewithpaclitaxel,aswellasthe“goldstan-
dard” orchiectomy. PSMA expression in the endothelium
of multiple types of solid tumors [8, 11]h a sb e e np r e v i -
ously reported and suggests a possible role of PSMA in
angiogenesis.
This study supports those by O’Keefe et al [8]a n d
Chang et al [11] andidentify acoordinated expression be-
tween PSMA and VEGF, a major stimulating protein for
angiogenesis. Treatment by either chemo- or hormonal
deprivation did not alter this correlation further, suggest-
ing that PSMA could represent a new angiogenic marker
for solid tumors. As previously reported [12]t r e a t m e n t
of the hormone-sensitive LNCaP tumor with paclitaxel
was more eﬀective in inhibiting growth than thalidomide,
and this could account for the signiﬁcant decrease in AR
expression in this study. The diminished expression of
VEGF following androgen deprivation also supports the
ﬁndings by Isaacs et al [18, 19] in the LNCaP model.
For prostate cancer PSMA presents a particularly at-
tractive target, since the advanced form of this disease is290 Paulus Tsui et al 2005:3 (2005)
notedbyextrememetastaticdisseminationrequiringneo-
vascularization. PSMA would present itself as a target for
prostatic malignancy as well as for angiogenesis.
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